Cas 221090-65-9,4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole

221090-65-9

Post Buying Request

Basic information

Product Name: 4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole
Synonyms: 4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole
CAS NO:221090-65-9
Molecular Formula:
Molecular Weight: 485.748
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole(CAS DataBase Reference)
NIST Chemistry Reference: 4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole(221090-65-9)
EPA Substance Registry System: 4-(3,4-Difluorobenzyl)-5-ethyl-3-methoxymethyl-1-(2,4,6-trichloro)phenylimidazo[4,5-c]pyrazole(221090-65-9)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 221090-65-9(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

221090-65-9 Suppliers

Recommended suppliers

221090-65-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 221090-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,1,0,9 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 221090-65:
(8*2)+(7*2)+(6*1)+(5*0)+(4*9)+(3*0)+(2*6)+(1*5)=89
89 % 10 = 9
So 221090-65-9 is a valid CAS Registry Number.

221090-65-9Upstream product

221090-65-9Downstream Products

221090-65-9Relevant academic research and scientific papers

Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists

-

, (2008/06/13)

Corticotropin releasing factor (CRF) antagonists of Formulae (I) or (II): and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 221090-65-9